The current study showed that PEITC is indeed effective in killing p53-null CLL cells, which are otherwise resistant to standard anti-CLL drugs such as F-ara-A, Oxaliplatin and Bendamustine. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.